Nanotechnology in Drug Delivery

Global Nanotechnology in Drug Delivery Market to Reach US$122.7 Billion by 2030

The global market for Nanotechnology in Drug Delivery estimated at US$77.4 Billion in the year 2024, is expected to reach US$122.7 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$35.6 Billion by the end of the analysis period. Growth in the Liposomes segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.0 Billion While China is Forecast to Grow at 11.8% CAGR

The Nanotechnology in Drug Delivery market in the U.S. is estimated at US$20.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$30.6 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Nanotechnology in Drug Delivery Market - Key Trends and Drivers Summarized

Nanotechnology in drug delivery represents a groundbreaking advancement in medicine, providing a method to increase the efficiency, precision, and efficacy of drug therapies, particularly for challenging diseases like cancer and diabetes. Utilizing nanoparticles, which are typically under 100 nanometers in size, this technology allows for the precise targeting and controlled release of medications, minimizing side effects while maximizing therapeutic outcomes. These nanoparticles are crafted from a range of biodegradable materials including natural and synthetic polymers, lipids, and metals, making them highly adaptable to various biological environments. For instance, in diabetes management, nanotechnology has enabled the development of closed-loop insulin delivery systems that dynamically adjust to changing glucose levels, mimicking physiological insulin responses and significantly improving patient care. Additionally, nanoparticles can navigate complex biological barriers such as the blood-brain barrier, which is particularly advantageous for delivering chemotherapy agents directly to brain tumors, thus bypassing traditional delivery challenges.

The application of nanotechnology in drug delivery is transforming the treatment landscape for diseases that are difficult to manage with conventional methods. By facilitating the transportation of drugs across restrictive barriers within the body, nanoparticles enhance the bioavailability and efficacy of treatments. Advanced nanocarriers are designed to target specific cells or receptors, which is vital for treating conditions like multidrug-resistant cancer effectively. These carriers can utilize the body`s circulatory system to deliver drugs directly to targeted sites, such as tumor cells or specific areas of inflammation. Moreover, innovations in nanoparticle design are producing systems that respond to the unique environments of disease sites, such as pH-responsive or oxidative stress-responsive nanoparticles that activate in the tumor microenvironment, thereby enhancing the precision of treatments like radiotherapy. This ability to respond to specific physiological conditions maximizes the impact of the therapeutic agents while sparing healthy tissue from unnecessary exposure.

The growth of nanotechnology in drug delivery is driven by several key factors. Technological advancements in nanoparticle fabrication and nanoscale imaging have significantly broadened the applications and effectiveness of nanomedicines. Increased regulatory support and dedicated funding are accelerating the development and approval of innovative nanotechnology applications, supporting research that spans across various diseases and medical challenges. Moreover, the shift towards patient-centric healthcare underscores the demand for drug delivery systems that enhance patient compliance and quality of life. Nanotechnologies offer customized and less invasive treatment options that align with modern healthcare goals of reducing treatment durations and improving therapeutic outcomes. Additionally, collaborations across diverse scientific disciplines are propelling forward the capabilities of nanotechnologies, integrating insights from materials science, chemistry, biology, and pharmaceutical sciences to innovate and refine drug delivery systems. As global health challenges evolve, the flexibility and adaptability of nanotechnologies to address emerging public health concerns like antibiotic resistance and pandemic responses become increasingly crucial, promising a future where nanotechnology plays a pivotal role in advancing drug delivery and patient care.

SCOPE OF STUDY:

The report analyzes the Nanotechnology in Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Nanoparticles, Liposomes, Nanocrystals, Nano Emulsions, Other Technologies); Application (Oncology, Cardiovascular, Neurology, Anti-Inflammatory, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• Aquanova AG
• BlueWillow Biologics
• Camurus AB
• Celgene, Inc.
• Ceramisphere Health Pty Limited
• Cristal Therapeutics
• CYTIMMUNE SCIENCES, Inc.
• EnColl Corporation
• EyePoint Pharmaceuticals
• Lena Nanoceutics Ltd.
• Nanobiotix
• NanoCarrier Co., Ltd.
• NanOlogy LLC
• Nanospectra Biosciences, Inc.
• Parvus Therapeutics Inc.
• Selecta Biosciences
• Starpharma Holdings Limited
• Taiwan Liposome Co.,
• Tarveda Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.